Development of human adaptive immunity to Staphylococcus aureus

人类对金黄色葡萄球菌适应性免疫的发展

基本信息

  • 批准号:
    10366018
  • 负责人:
  • 金额:
    $ 62.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-05 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

Staphylococcus aureus is an aggressive antibiotic-resistant human bacterial pathogen. S. aureus is a leading cause of infectious disease morbidity, mortality, and hospital-associated infection in the U.S., and a formidable health threat worldwide. The only durable solution to mitigate S. aureus disease is the successful development of a universal vaccine. In spite of the clinical burden of human S. aureus infection, and considerable molecular knowledge of disease pathogenesis gleaned from experimental systems, there is a striking paucity of knowledge regarding the host immune response in human S. aureus infection. This fact has remained the single most significant shortcoming of prior vaccine approaches, as the scientific premise for the inclusion of vaccine antigens has not been based on known correlates of human immunity to S. aureus. The investigators’ studies to date in the pediatric population strongly suggest that the adaptive immune response to S. aureus is templated early in life when initial exposure to the organism occurs, amplifying the importance of understanding the development of the human adaptive immune response to S. aureus during infancy and early childhood. The proposed project addresses current knowledge gaps through a multifaceted analysis of the natural development of protective immunity to S. aureus, leveraging novel insight on the role of S. aureus α-toxin (Hla) as a virulence factor that dampens the antigen-specific T cell response in the host. Coupled with the observation that the serologic response to Hla is a correlate of long-term protective immunity to S. aureus in children, these findings suggest that neutralizing Hla may simultaneously afford disease protection and preclude modulation of host immunity by S. aureus. To this end, a cohort-based approach for comparative analysis of human immunity in the context of normal, healthy childhood development, as well as in the setting of S. aureus disease, will be performed. The context of this exposure is expected to elicit protective immunologic responses or maladaptive responses, which we hypothesize will be discernable through paired analyses of healthy and infected subjects as a function of development. These studies will be the first to leverage high-dimensionality mass cytometry (CyTOF)-based analysis of the human T cell response to S. aureus, characterizing both cellular differentiation and the functional response. Paired with multiplex analysis of the developing human antibody response to S. aureus virulence factors, the biorepository generated through the proposed study will support a comparative analysis of adaptive immunity in healthy infants and young children relative to that observed in patients who manifest both local and invasive S. aureus infection. The proposed multi-disciplinary team is uniquely positioned to conduct the first highly-focused, hypothesis-driven approach to examination of the development of human immunity to S. aureus. This research will inform our understanding of the natural development of the host response to S. aureus, providing an essential foundation for the strategic design and implementation of a S. aureus vaccine capable of eliciting population-level immunity.
金黄色葡萄球菌是一种具有侵袭性耐药的人类细菌病原体。金黄色葡萄球菌是美国传染病发病率、死亡率和医院相关感染的主要原因,也是全球范围内令人生畏的健康威胁。减轻金黄色葡萄球菌疾病的唯一持久解决方案是成功开发一种通用疫苗。尽管人类金黄色葡萄球菌感染的临床负担很大,并且从实验系统中收集了大量关于疾病发病机制的分子知识,但关于人类金黄色葡萄球菌感染的宿主免疫反应的知识却明显缺乏。这一事实仍然是以往疫苗方法的一个最重要的缺点,因为纳入疫苗抗原的科学前提并不是基于已知的人类对金黄色葡萄球菌免疫的相关因素。迄今为止,研究人员在儿科人群中的研究强烈表明,对金黄色葡萄球菌的适应性免疫反应是在生命早期初始暴露于该生物体时形成的,这增强了理解婴儿期和幼儿期人类对金黄色葡萄球菌适应性免疫反应发展的重要性。拟议的项目通过对金黄色葡萄球菌保护性免疫自然发展的多方面分析,利用对金黄色葡萄球菌α-毒素(Hla)作为抑制宿主抗原特异性T细胞反应的毒力因子的作用的新见解,解决了目前的知识空白。再加上对Hla的血清学反应与儿童对金黄色葡萄球菌的长期保护性免疫相关的观察结果,这些发现表明,中和Hla可能同时提供疾病保护并排除金黄色葡萄球菌对宿主免疫的调节。为此目的,将采用一种基于队列的方法,在正常、健康的儿童发育和金黄色葡萄球菌疾病的背景下,对人类免疫进行比较分析。这种暴露的环境预计会引起保护性免疫反应或适应不良反应,我们假设将通过对健康和感染受试者的配对分析作为发育的功能来识别。这些研究将首次利用基于高维质量细胞术(CyTOF)的人类T细胞对金黄色葡萄球菌的反应分析,表征细胞分化和功能反应。与发展中的人类抗体对金黄色葡萄球菌毒力因子的多重分析相结合,通过提出的研究产生的生物库将支持对健康婴幼儿的适应性免疫进行比较分析,相对于在表现为局部和侵袭性金黄色葡萄球菌感染的患者中观察到的适应性免疫。拟议的多学科团队具有独特的优势,可以开展第一个高度集中的、假设驱动的方法来检查人类对金黄色葡萄球菌免疫的发展。这项研究将使我们了解宿主对金黄色葡萄球菌反应的自然发展,为能够引起人群免疫的金黄色葡萄球菌疫苗的战略设计和实施提供必要的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Juliane Bubeck Wardenburg其他文献

Juliane Bubeck Wardenburg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Juliane Bubeck Wardenburg', 18)}}的其他基金

ADAM10 polymorphism in susceptibility to S. aureus disease
ADAM10 多态性对金黄色葡萄球菌病的易感性
  • 批准号:
    10649082
  • 财政年份:
    2023
  • 资助金额:
    $ 62.85万
  • 项目类别:
Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection
开发针对人群级别的金黄色葡萄球菌感染预防暴露前疫苗
  • 批准号:
    10483136
  • 财政年份:
    2022
  • 资助金额:
    $ 62.85万
  • 项目类别:
Enterotoxigenic Bacteroides fragilis in modulation of host immunity
产肠毒素脆弱拟杆菌对宿主免疫的调节作用
  • 批准号:
    10318195
  • 财政年份:
    2021
  • 资助金额:
    $ 62.85万
  • 项目类别:
Development of human adaptive immunity to Staphylococcus aureus
人类对金黄色葡萄球菌适应性免疫的发展
  • 批准号:
    10199312
  • 财政年份:
    2021
  • 资助金额:
    $ 62.85万
  • 项目类别:
Development of human adaptive immunity to Staphylococcus aureus
人类对金黄色葡萄球菌适应性免疫的发展
  • 批准号:
    10577832
  • 财政年份:
    2021
  • 资助金额:
    $ 62.85万
  • 项目类别:
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility
产肠毒素脆弱拟杆菌的获得与疾病易感性
  • 批准号:
    10228659
  • 财政年份:
    2018
  • 资助金额:
    $ 62.85万
  • 项目类别:
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility
产肠毒素脆弱拟杆菌的获得与疾病易感性
  • 批准号:
    10468700
  • 财政年份:
    2018
  • 资助金额:
    $ 62.85万
  • 项目类别:
Analysis of ADAM10 in infection-associated MODS
ADAM10 在感染相关 MODS 中的分析
  • 批准号:
    9379668
  • 财政年份:
    2017
  • 资助金额:
    $ 62.85万
  • 项目类别:
Pediatric Cardiovascular and Pulmonary Research Training Program
儿科心血管和肺研究培训计划
  • 批准号:
    10115783
  • 财政年份:
    2015
  • 资助金额:
    $ 62.85万
  • 项目类别:
Pediatric Cardiovascular and Pulmonary Research Training Program
儿科心血管和肺研究培训计划
  • 批准号:
    10576362
  • 财政年份:
    2015
  • 资助金额:
    $ 62.85万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.85万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了